Cristian Sanchez-Torres
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Cristian Sanchez-Torres has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Ana Ramirez Tovar
Department of Pediatrics, Emory University, Atlanta, Georgia, USA
2 shared publications - Miriam B. Vos
Department of Pediatrics, Emory University, Atlanta, Georgia, USA
2 shared publications - Andrea R. Mospan
Target RWE, Durham, North Carolina, USA
1 shared publication - Anna Mae Diehl
Division of Gastroenterology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
1 shared publication - Daniel H. Leung
Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Baylor College of Medicine, Texas Children’s Hospital, Houston, Texas, USA
1 shared publication - Feng Yu
Target RWE, Durham, North Carolina, USA
1 shared publication
Latest Publications
- Open Access
- 10 October 2024
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 8 (11)
Concordance of MASLD and NAFLD nomenclature in youth participating in the TARGET-NASH real-world cohort
- 10 October 2024
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 8 (11)
Open AccessConcordance of MASLD and NAFLD nomenclature in youth participating in the TARGET-NASH real-world cohort
- Open Access
- 1 November 2023
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 7 (11)
The Impact and Burden of Dietary Sugars on the Liver
NAFLD, or metabolic dysfunction–associated steatotic liver disease, has increased in prevalence hand in hand with the rise in obesity and increased free sugars in the food supply. The causes of NAFLD are genetic in origin combined with environmental drivers of the disease phenotype. Dietary intake of added sugars has been shown to have a major role in the phenotypic onset and progression of the disease. Simple sugars are key drivers of steatosis, likely through fueling de novo lipogenesis, the conversion of excess carbohydrates into fatty acids, but also appear to upregulate lipogenic metabolism and trigger hyperinsulinemia, another driver. NAFLD carries a clinical burden as it is associated with obesity, type 2 diabetes, metabolic syndrome, and cardiovascular disease. Patient quality of life is also impacted, and there is an enormous economic burden due to healthcare use, which is likely to increase in the coming years. This review aims to discuss the role of dietary sugar in NAFLD pathogenesis, the health and economic burden, and the promising potential of sugar reduction to improve health outcomes for patients with this chronic liver disease.
- 1 November 2023
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 7 (11)
Open AccessThe Impact and Burden of Dietary Sugars on the Liver
NAFLD, or metabolic dysfunction–associated steatotic liver disease, has increased in prevalence hand in hand with the rise in obesity and increased free sugars in the food supply. The causes of NAFLD are genetic in origin combined with environmental drivers of the disease phenotype. Dietary intake of added sugars has been shown to have a major role in the phenotypic onset and progression of the disease. Simple sugars are key drivers of steatosis, likely through fueling de novo lipogenesis, the conversion of excess carbohydrates into fatty acids, but also appear to upregulate lipogenic metabolism and trigger hyperinsulinemia, another driver. NAFLD carries a clinical burden as it is associated with obesity, type 2 diabetes, metabolic syndrome, and cardiovascular disease. Patient quality of life is also impacted, and there is an enormous economic burden due to healthcare use, which is likely to increase in the coming years. This review aims to discuss the role of dietary sugar in NAFLD pathogenesis, the health and economic burden, and the promising potential of sugar reduction to improve health outcomes for patients with this chronic liver disease.